A Pharmacokinetic Study of the Effect of Itraconazole Exposure to Orvepitant in Healthy Volunteers

Key Inclusion Criteria: * male volunteers * judged to be in good health, based on the results of medical history, physical examination, vital signs, 12 lead ECG, and clinical laboratory findings * body weight greater than 50 kg and body mass index (BMI) within the range 18 to 30 kg/m2 (inclusive) Key Exclusion Criteria: * clinically significant findings on physical examination * relevant medical history * history of or considered at high risk of seizures (except febrile fits in childhood), including history of significant head injury * positive serology for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (anti-HCV) or human immunodeficiency virus (HIV) * serum biochemistry and full blood count considered by the Investigator to be of clinical significance * systolic blood pressure \<100 or \>140 mmHg or diastolic BP \<50 or ˃90 mmHg, measured prior to the first dose of orvepitant * abnormal 12 lead electrocardiogram (ECG) * has donated one or more units (approximately 450 mL) of blood or acute loss of an equivalent amount of blood within 90 days prior to study intervention administration